Capital World Investors
BDTX icon

Capital World Investors’s Black Diamond Therapeutics BDTX Stock Holding History

Capital World Investors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-525,000
Closed -$4.44M – 614
2021
Q3 		$4.44M Hold
525,000
– – ﹤0.01% 582
2021
Q2 		$6.4M Hold
525,000
– – ﹤0.01% 575
2021
Q1 		$12.7M Hold
525,000
– – ﹤0.01% 533
2020
Q4 		$16.8M Hold
525,000
– – ﹤0.01% 499
2020
Q3 		$15.9M Hold
525,000
– – ﹤0.01% 484
2020
Q2 		$22.1M Hold
525,000
– – 0.01% 427
2020
Q1 		$13.1M Buy
+525,000
New +$16M ﹤0.01% 432

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors's BDTX Position: Q4 2021 in Review

Capital World Investors sold out of Black Diamond Therapeutics (BDTX) in Q4 2021, closing a stake of 525,000 shares — an estimated $4.44M sold.

Capital World Investors first reported a position in BDTX in Q1 2020 and held it in 7 quarters. The position peaked at $22.1M in Q2 2020. 95 funds tracked by Wall St. Rank hold BDTX as of Q4 2021.

  • Capital World Investors reported no remaining Black Diamond Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Capital World Investors sold 525,000 Black Diamond Therapeutics shares in Q4 2021, an estimated $4.44M.
  • Capital World Investors first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 7 quarters.
  • Capital World Investors's Black Diamond Therapeutics position peaked at $22.1M in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2021.

Based on Capital World Investors's 13F filing for Q4 2021, filed 14 Feb 2022.